Emmaceutics (Pty) Ltd is a South African pharmaceutical innovation and biotechnology company focused on translating scientific discoveries into innovative therapeutic technologies that address significant unmet healthcare needs. Founded by Emmanuel Mukisa Kiyonga, a pharmaceutical scientist, inventor and entrepreneur, Emmaceutics operates at the intersection of pharmaceutical science, drug development, materials science, biotechnology and healthcare innovation.
The organisation's core focus is the discovery, development, validation and commercialisation of novel pharmaceutical technologies, including innovative drug substances, crystal-engineered pharmaceutical systems, advanced drug-delivery technologies and therapeutic candidates. Emmaceutics seeks to bridge the gap between academic research and real-world healthcare application by supporting the progression of promising innovations from scientific discovery and intellectual-property protection through further development, validation and eventual clinical and commercial translation.
A key technology within the Emmaceutics innovation portfolio is a novel Raloxifene Hydrate, invented by Emmanuel Kiyonga through research conducted at Sefako Makgatho Health Sciences University (SMU). The associated intellectual property is owned by SMU, with Kiyonga recognised as the inventor. Emmaceutics serves as the entrepreneurial and innovation platform through which the technology is being positioned for further pharmaceutical development, technology translation and eventual commercialisation, subject to the applicable intellectual-property and technology-transfer arrangements with SMU.
Emmaceutics combines pharmaceutical expertise with an entrepreneurial approach to innovation and works through collaborations with academic institutions, researchers, industry stakeholders and other innovation partners. Its broader pipeline includes drug-development and pharmaceutical-engineering projects addressing areas such as oncology, substance-use disorders and women's health.
Through this model, Emmaceutics aims to contribute to the development of locally originated, scientifically validated and globally scalable healthcare solutions, while strengthening the pathway from South African research and intellectual property to products capable of delivering meaningful clinical, economic and societal impact.